Fixed-dose combinations of bronchodilators in the treatment of patients with COPD: problem of choice

Chronic Obstructive Pulmonary Disease (COPD) is a disease characterized by air flow limitation that progresses over time and is not fully reversible, which, along with the severity of clinical symptoms and the frequency of relapses, is one of its key characteristics [1, 2]. The main “tool” in achiev...

Full description

Bibliographic Details
Main Author: A. I. Sinopalnikov
Format: Article
Language:Russian
Published: Remedium Group LLC 2018-10-01
Series:Медицинский совет
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/2677
id doaj-e20b464e0d1b48758351a44bab065b02
record_format Article
spelling doaj-e20b464e0d1b48758351a44bab065b022021-07-28T13:29:38ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-10-010159610010.21518/2079-701X-2018-15-96-1002629Fixed-dose combinations of bronchodilators in the treatment of patients with COPD: problem of choiceA. I. Sinopalnikov0Russian Medical Academy of Continuing Postgraduate Education, Federal State Budgetary Educational Institution of Further Professional Education of the Ministry of Health of RussiaChronic Obstructive Pulmonary Disease (COPD) is a disease characterized by air flow limitation that progresses over time and is not fully reversible, which, along with the severity of clinical symptoms and the frequency of relapses, is one of its key characteristics [1, 2]. The main “tool” in achieving therapeutic goals in accordance with current guidelines GOLD [1], GesEPOC [3], NICE [4], PPO [5], etc. - are bronchodilators. Fixed-dose combinations of long acting beta-2 agonists/long acting anticholinergic agents provide optimal bronchodilation and play a primary role in preventing exacerbations of COPD.https://www.med-sovet.pro/jour/article/view/2677chronic obstructive pulmonary diseasefixed-dose combinations of laba/laacvilantherol/umeclidinium
collection DOAJ
language Russian
format Article
sources DOAJ
author A. I. Sinopalnikov
spellingShingle A. I. Sinopalnikov
Fixed-dose combinations of bronchodilators in the treatment of patients with COPD: problem of choice
Медицинский совет
chronic obstructive pulmonary disease
fixed-dose combinations of laba/laac
vilantherol/umeclidinium
author_facet A. I. Sinopalnikov
author_sort A. I. Sinopalnikov
title Fixed-dose combinations of bronchodilators in the treatment of patients with COPD: problem of choice
title_short Fixed-dose combinations of bronchodilators in the treatment of patients with COPD: problem of choice
title_full Fixed-dose combinations of bronchodilators in the treatment of patients with COPD: problem of choice
title_fullStr Fixed-dose combinations of bronchodilators in the treatment of patients with COPD: problem of choice
title_full_unstemmed Fixed-dose combinations of bronchodilators in the treatment of patients with COPD: problem of choice
title_sort fixed-dose combinations of bronchodilators in the treatment of patients with copd: problem of choice
publisher Remedium Group LLC
series Медицинский совет
issn 2079-701X
2658-5790
publishDate 2018-10-01
description Chronic Obstructive Pulmonary Disease (COPD) is a disease characterized by air flow limitation that progresses over time and is not fully reversible, which, along with the severity of clinical symptoms and the frequency of relapses, is one of its key characteristics [1, 2]. The main “tool” in achieving therapeutic goals in accordance with current guidelines GOLD [1], GesEPOC [3], NICE [4], PPO [5], etc. - are bronchodilators. Fixed-dose combinations of long acting beta-2 agonists/long acting anticholinergic agents provide optimal bronchodilation and play a primary role in preventing exacerbations of COPD.
topic chronic obstructive pulmonary disease
fixed-dose combinations of laba/laac
vilantherol/umeclidinium
url https://www.med-sovet.pro/jour/article/view/2677
work_keys_str_mv AT aisinopalnikov fixeddosecombinationsofbronchodilatorsinthetreatmentofpatientswithcopdproblemofchoice
_version_ 1721273985303314432